AstraZeneca PLC (AZN)vsConcord Medical Services Holdings (CCM)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
CCM
Concord Medical Services Holdings
$4.78
-5.53%
HEALTHCARE · Cap: $20.19M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13024% more annual revenue ($60.44B vs $460.51M). AZN leads profitability with a 17.2% profit margin vs -20.2%. CCM appears more attractively valued with a PEG of 0.57. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CCM
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+68.0%
Fair Value
$11.95
Current Price
$4.78
$7.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 57.4% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -21.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : CCM
The strongest argument for CCM centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 57.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : CCM
The primary concerns for CCM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while CCM is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
CCM is growing revenue faster at 57.4% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 43/100), backed by strong 17.2% margins and 12.5% revenue growth. CCM offers better value entry with a 68.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Concord Medical Services Holdings
HEALTHCARE · MEDICAL CARE FACILITIES · China
Concord Medical Services Holdings Limited, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?